ISPOR Finds Its Place In Patient-Centric World
Founding executive director of the International Society of Pharmacoeconomics and Outcomes Research Marilyn Dix Smith talks to “The Pink Sheet” on the drug industry becoming more “patient-centric” and the role that ISPOR is playing to keep that patient focus going.
You may also be interested in...
Work needs to be done to allow for the use of social media to support content validity of patient-reported outcomes, but one FDA endpoints reviewer says there is a place for social media to work alongside traditional methods of validating PROs.
Drug Development Needs “Clean-Slate Think” To Involve Patients All Along The Way – Pfizer’s Lewis-Hall
Drug companies and other stakeholders should collaborate on developing a “clear framework” for patient engagement, Freda Lewis-Hall says at ISPOR.
A number of drug-related comparative effectiveness research projects are approved for PCORI-sponsored research in its second funding cycle. Health IT-related projects also get attention as the institute spends more than $88 million on 51 projects.